{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04965961",
      "OrgStudyIdInfo": {
        "OrgStudyId": "H-18013069"
      },
      "Organization": {
        "OrgFullName": "University of Copenhagen",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females",
      "OfficialTitle": "Plasma and Exosome Proteomic Changes Associated With Augmented Erythropoiesis and Muscle Contractions."
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 28, 2019",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 17, 2021",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 28, 2021",
      "StudyFirstSubmitQCDate": "July 8, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 16, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "July 8, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 16, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Nikolai Nordsborg",
        "ResponsiblePartyInvestigatorTitle": "Professor, Head of Department",
        "ResponsiblePartyInvestigatorAffiliation": "University of Copenhagen"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University of Copenhagen",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Recombinant human erythropoietin (rHuEPO) regimen enhances maximal oxygen consumption (VO2max), but the effect of micro-doses on maximal and submaximal performance is not clear and detection of micro-doses is difficult with current methods. This study investigated whether micro-doses of rHuEPO enhances maximal and endurance performance in males and females.",
      "DetailedDescription": "In a randomized, double-blind, placebo-controlled design, 48 trained adults (24 females, 24 males) receive either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week for four weeks. Before the intervention, time trial performance and maximal oxygen uptake will be assessed. Three and five days after the last injection, time trial performance and maximal oxygen uptake will be determined to assess the effect of the rHuEPO administration. In addition, total hemoglobin mass and intravascular volumes will be determined via the carbon monoxide rebreathing method in duplicate measures."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Sports Drug Abuse"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "erythropoeitin",
          "doping"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Explorative",
        "DesignPrimaryPurpose": "Other",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignMaskingDescription": "An algorithm was created using randomizer.org",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "48",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Recombinant human erythropoietin treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on non-consecutive days. Subjects receive tablets with 80mg iron (Tardyferon, Pierre Fabre Pharme GmbH, Freiburg, Germany) to ensure sufficient iron stores for the expected increase in erythropoeisis.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: EPO"
              ]
            }
          },
          {
            "ArmGroupLabel": "Control group",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Participants receive intravenous injections of ~0,5 mL saline (NaCl 0,9%) three times per week for four weeks on non-consecutive days.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Control group - saline injection"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "EPO",
            "InterventionDescription": "Please refer to the arm description",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Recombinant human erythropoietin treatment"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Control group - saline injection",
            "InterventionDescription": "Please refer to the arm description",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Control group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in maximal oxygen uptake",
            "PrimaryOutcomeDescription": "Change from baseline maximal aerobic capacity 5 days after last injection. Measured via an exhaustive incremental cycle ergometer test.",
            "PrimaryOutcomeTimeFrame": "Change from baseline to 5 days after last injection"
          },
          {
            "PrimaryOutcomeMeasure": "Change in time trial performance",
            "PrimaryOutcomeDescription": "Change from baseline endurance exercise performance 3 days after last injection. Measured via a preloaded 400 kcal time-trial.",
            "PrimaryOutcomeTimeFrame": "Change from baseline to 3 days after last injection"
          },
          {
            "PrimaryOutcomeMeasure": "Change in total hemoglobin mass",
            "PrimaryOutcomeDescription": "Change from baseline total hemoglobin mass 3 days after last injection. Measured by the carbon monoxide rebreathing method.",
            "PrimaryOutcomeTimeFrame": "Change from baseline to 3 days after last injection"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nRelative maximum oxygen uptake (VO2-max) of at least 50 ml O2/min/kg for male participants and 45 ml O2/min/kg for female participants\n\nExclusion Criteria:\n\nAge\nInsufficient fitness level\nBlood donation 3 months prior to enrollment\nAltitude exposure 2 months before enrollment\nHypertension",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "45 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Nutrition, Exercise and Sports",
            "LocationCity": "Copenhagen",
            "LocationZip": "2100",
            "LocationCountry": "Denmark"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided",
      "IPDSharingDescription": "Fully anonymous data can be shared with other researchers."
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000019966",
            "ConditionMeshTerm": "Substance-Related Disorders"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000064419",
            "ConditionAncestorTerm": "Chemically-Induced Disorders"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M20990",
            "ConditionBrowseLeafName": "Substance-Related Disorders",
            "ConditionBrowseLeafAsFound": "Drug Abuse",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M29455",
            "ConditionBrowseLeafName": "Chemically-Induced Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC25",
            "ConditionBrowseBranchName": "Substance Related Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M9685",
            "InterventionBrowseLeafName": "Iron",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M314",
            "InterventionBrowseLeafName": "Epoetin Alfa",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Micro",
            "InterventionBrowseBranchName": "Micronutrients"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          }
        ]
      }
    }
  }
}